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Abstract
Irritable bowel syndrome (IBS) is a chronic gastrointestinal (GI) disorder that reportedly affects 5% to 20% of the world population.
The etiology of IBS is not completely understood, but diet appears to play an important role in its pathophysiology. Asian diets differ
considerably from those in Western countries, which might explain differences in the prevalence, sex, and clinical presentation seen
between patients with IBS in Asian and Western countries. Dietary regimes such as a low-fermentable oligo-, di-, monosaccharides,
and polyols (FODMAP) diet and the modified National Institute for Health and Care Excellence (NICE) diet improve both symptoms
and the quality of life in a considerable proportion of IBS patients. It has been speculated that diet is a prebiotic for the intestinal
microbiota and favors the growth of certain bacteria. These bacteria ferment the dietary components, and the products of fermentation
act upon intestinal stem cells to influence their differentiation into enteroendocrine cells. The resulting low density of enteroendocrine
cells accompanied by low levels of certain hormones gives rise to intestinal dysmotility, visceral hypersensitivity, and abnormal
secretion. This hypothesis is supported by the finding that changing to a low-FODMAP diet restores the density of GI cells to the
levels in healthy subjects. These changes in gut endocrine cells caused by low-FODMAP diet are also accompanied by improvements
in symptoms and the quality of life.
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Introduction
Irritable bowel syndrome (IBS) is a chronic functional disorder.
Although the etiology of IBS is unknown, several factors seem to
play a role in its pathophysiology; these include genetic factors,
diet, intestinal microbiota, low-grade inflammation, and abnor-
malities of the gastrointestinal (GI) endocrine cells [1].
IBS patients suffer from intermittent lower abdominal pain,
altered bowel habits, and abdominal bloating/distension [2]. IBS
is mainly diagnosed based on an assessment of the symptoms
described by the Rome criteria [3]. Based on the stool pattern,
IBS patients are divided into four subtypes: diarrhea-predomi-
nant, constipation-predominant, mixed diarrhea and constipa-
tion, and unclassified [4, 5]. IBS patients are further divided into
two subsets: sporadic (non-specific) and post-infection [6].
Sporadic IBS includes patients who have had symptoms that
are not associated with GI infections. Post-infection IBS occurs
in otherwise healthy subjects as the sudden onset of IBS symp-
toms after an episode of gastroenteritis [6], and reportedly con-
stitutes 6% to 17% of patients with IBS [7].
IBS patients visit physicians more often than patients with
diabetes mellitus, hypertension, or asthma; 12% to 14% of pri-
mary care visits and 28% of gastroenterologist referral are due
to IBS [8–10]. The onset of IBS is usually in young age (<
45 years) during the most active phase of their lives [11, 12].
There is a sex difference in the prevalence of IBS, with a
female:male ratio of 2:1 [11]. IBS reduces the quality of life to
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the same degree as other chronic diseases such as diabetes
mellitus and kidney failure [13].
The present review discusses the role of diet in the patho-
physiology of IBS, the use of diet in its management, and the
possible mechanisms behind the effects of diet on IBS.
Role of diet in IBS
IBS patients associate their symptomwith food intake, especially
specific food items such aswheat products, milk and its products,
cabbage, onion, hot spices, and fried and smoked foodstuffs [14,
15]. Despite IBS patients avoiding certain food items, diet sur-
veys have not found any differences in intake between IBS pa-
tients and community controls [16]. Furthermore, there is no
difference between IBS patients and the background population
in the intake of calories, carbohydrates, proteins, or fats [15].
However, the diets of IBS patients tend to be low in calcium,
magnesium, phosphorus, vitamin B2, and vitamin A [15].
While the prevalence of IBS in Asia is 5% to 9% [17–28], it
is 10% to 20% inWestern countries (USA and Europe) [14–25].
Furthermore, no female predominance was found in Asian IBS
patients [2], in contrast toWestern IBS patients [22–25]. The
clinical presentation of IBS differs between Asian and Western
patients. Abdominal bloating is a more-common complaint than
pain in Asians, and this abdominal pain is localized to the upper
abdomen rather than in the lower abdomen in Asian patients.
Moreover, alteration in bowel habits is much less prominent in
Asian IBS patients than in their Western counterparts [2–13].
The Western diet is rich in fats and beef protein and low
in carbohydrates and fiber, whereas the Asian diet is rich in
carbohydrates and fiber, and low in fats and meat protein [29].
Asian meals consist mainly of rice, vegetables, fish, eggs, poul-
try, pork, vegetable oil, and spices [29]. Rice is absorbed in the
small intestine and produces negligible amounts of intestinal gas
[29]. Furthermore, cellophane noodles made from mung bean
flour, a traditional Asian food, produce much less intestinal gas
than do wheat noodles [30]. These main differences between the
diet in Asia andWestern countries might at least partially explain
the differences mentioned above between patients with IBS in
Asian and Western countries, including in its prevalence,
sex difference, and clinical presentation.
Diet in the management of IBS
The intake of a low-fermentable oligo-, di-, monosaccharides,
and polyols (FODMAP) diet reportedly improves both symp-
toms and the quality of life in 50% to 76% of IBS patients
(Table 1) [16, 31–38]. Two recent systematic reviews of ran-
domized trials produced significant evidence for the short-
term benefits of a low-FODMAP diet on GI symptoms and
quality of life in patients with IBS [39, 40]. However, the
studies included in these reviews were of low quality, due to
methodological heterogeneity and a high risk of bias, which
commonly occurs in studies of dietary treatments. However, a
low-FODMAP diet requires intensive meal-planning, is ex-
pensive and difficult to maintain over a long period, and can
result in negative changes in the intestinal microbiota [35,
41–43]. Furthermore, consuming a low-FODMAP diet for a
long time may result in deficiencies in vitamins, minerals, and
naturally occurring antioxidants [42, 43]. The benefits of low-
FODMAP diet have been demonstrated in all IBS subtypes,
but IBS symptoms were found to improve less in patients with
constipation-predominant IBS in two studies [36, 44].
The modified National Institute for Health and Care
Excellence (NICE) diet has the same effect as a low-FODMAP
diet in around half (46% to 54%) of IBS patients, but it is easy to
maintain and does not have the hazards seen with a low-
FODMAP diet [35, 36]. The modified NICE diet is the first diet
recommended for IBS patients by the British Dietetic
Association [15, 16, 45, 46]. In the modified NICE diet, patients
are advised to consume regular meals; to replace wheat products
with spelt products; to reduce the intakes of fatty food, onions,
cabbage, and beans; to avoid carbonated beverages, and sweet-
eners whose names end with “-ol”; and to regularly consume
psyllium husk fibers. The British Dietetic Association also rec-
ommends reducing the intakes of coffee, spicy foods, and alcohol
[15, 16].
Role of diet in the pathophysiology of IBS
Diet induces IBS symptoms via several mechanisms, including
intestinal distention, direct chemical stimulation of the epithelial
cells lining the intestinal lumen, and altered intestinal microbiota.
There is no evidence that IBS patients suffer from a food allergy
mediated by immunoglobulin E [47–55]. It has also been docu-
mented that food intolerance does not occur in IBS, which is a
non-toxic, non-immune-mediated reaction to bioactive chemicals
in food [2, 55].
The intestine can be distended by the amount/volume of
ingested food, fluid secretion induced by ingested food, and
gas production caused by intestinal bacteria fermenting food.
GI wall distention is well known to induce symptoms of full-
ness, distention, and abdominal pain [56]. Early symptoms
can also develop as a direct effect of food components such
as chili, since this contains capsaicin that induces abdominal
burning and pain [57]. The modulation of GI motility and
sensation via neurohormonal mechanisms such as fatty food
was found to induce gut hypersensitivity and delay the GI
transit of gas and the contents [14, 58]. There are several
possible mechanisms by which a FODMAP-containing diet
can trigger IBS symptoms (Fig. 1), such as by increasing the
osmotic pressure in the large intestine, acting as prebiotics for
gas-producing Clostridium bacteria, providing a substrate for
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bacterial fermentation causing abdominal distension and pain/
discomfort, and interacting with the enteroendocrine cells that
regulate GI sensation, motility, secretion, and absorption.
A small proportion of IBS patients may have undiagnosed
celiac disease and may develop GI symptoms after ingesting
foodstuffs that contain wheat or gluten. A meta-analysis sug-
gested that the prevalence of biopsy-demonstrated celiac disease
in cases meeting diagnostic criteria for IBS was 4%, which was
fourfold higher than that in controls without IBS [59]. Celiac
disease was diagnosed by serology and biopsy in 1% of
Chinese patients with diarrhea-predominant IBS according to
the Rome-III criteria [60].
Non-celiac gluten sensitivity (NCGS; better termed non-
celiac wheat sensitivity) is defined as having GI and extra-
GI IBS-like symptomswithout celiac disease or wheat allergy,
but the symptoms are relieved by a gluten-free diet (GFD) and
relapse upon a gluten challenge [61–66]. The prevalence of
NCGS has been reported as 0.55% to 6% of the US population
[63, 67]. A randomized, double-blind, cross-over, food chal-
lenge study using gluten protein and control protein in IBS
patients who were already consuming a low-FODMAP diet
demonstrated that gluten protein produced symptoms similar
to whey protein (as a control) [68]. Furthermore, 24% of those
who believed that they had NCGS experienced uncontrolled
symptoms despite consuming a GFD [69]. This suggests that
the aggravation of GI symptoms in IBS patients who consume
a gluten diet is the result of the carbohydrate content (fructans
and galactans) of wheat rather than gluten.
As mentioned above, diet, the intestinal bacterial flora, and
abnormalities of the GI endocrine cells play an important role
in the pathophysiology of IBS [1, 70–72]. Moreover, these
factors seem to interact with each other [13].
The enteroendocrine cells are scattered between the epithelial
cells facing the gut lumen [6, 73]. The enteroendocrine cells have
sensors in the form of microvilli protruding into the lumen, and
these sense the gut contents (mostly nutrients) and respond to
them by releasing hormones into the lamina propria (Fig. 2)
[74–86]. The hormones released from the enteroendocrine cells
vary with the gut intraluminal contents and the proportions of
carbohydrates, proteins, and fats [6, 73]. These released
Table 1 Summary of randomized trials of a low-FODMAP diet compared with the usual diet or common dietary advice in the management of patients
with irritable bowel syndrome







N =41; unknown IBS
subtype
Low-FODMAP Usual diet 4 weeks;
advice
• Significantly greater proportion of patients
with adequate symptom control (68% vs.
23%, low-FODMAP vs. control)
• Significantly lower concentration and




N =38; moderate to severe
symptoms; IBS-C (n =
22), IBS-D (n =18),
IBS-M (n =35)
Low-FODMAP Traditional IBS diet (greater
emphasis on how and




• Overall symptoms (IBS-SSS score) signifi-
cantly reduced after treatment in both




N =92; IBS-D Low-FODMAP Modified NICE 4 weeks;
advice
• Significantly greater proportion of patients
with symptom relief ≥50% (52% vs. 41%,
low-FODMAP vs. control)
• Significantly improved abdominal pain,
bloating, stool consistency, frequency, and
urgency
• Significantly improved IBS-QoL score,
anxiety, and activity impairment
Zahedi et al.,
2018 [38]
N =101; IBS-D; 78% with
moderate to severe
symptoms





• Significantly improved scores overall and
for the individual items on IBS-SSS, stool




N =62; IBS-C (n =20),
other non IBS-C sub-
types (n =42)




• Significantly greater proportion of patients
with ≥30% decrease in average of daily
worst abdominal pain/discomfort (60% vs.
28%, structural vs. brief advice)
• Significant lower post-prandial hydrogen
gas production in SILFD compared with
brief advice
IBS-D diarrhea-predominant IBS, IBS-C constipation-predominant, IBS-M mixed diarrhea and constipation IBS, IBS-SSS IBS symptom severity
score, IBS-QoL, IBS-quality of life; SILFD structural individual low-fermentable oligo- di- monosaccharide and polyol (FODMAP) advice; NICE
National Institute for Health and Care Excellence
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Fig. 1 Schematic illustration of the possible mechanisms by which
fermentable oligo- di- monosaccharide and polyol (FODMAP) can trig-
ger IBS symptoms. Upon reaching the large intestine, FODMAP in-
creases the osmotic pressure and act as prebiotics for gas-producing
Clostridium bacteria, inducing an increase in gas production. The produc-
tion of gas increases the luminal pressure and stimulates the release of
serotonin from enterochromaffin (EC) cells. Serotonin acts on the
intrinsic sensory nerve fibers (ISNF) of the submucosal and myenteric
ganglia, which in turn convey the activation via the extrinsic sensory
nerve fibers (ESNF) to the central nervous system. They also act indirect-
ly on the enteroendocrine cells that regulate gastrointestinal sensation,
motility, secretion, and absorption. Reproduced from El-Salhy and
Gundersen [31] with permission from the authors and publisher
Fig. 2 The gut endocrine cells have specialized microvilli that project
into the lumen and act as sensors for the luminal contents (mostly for
nutrients). These respond to the luminal contents by releasing hormones
into the lamina propria. These hormones act locally on the nearby
structures (paracrine mode of action) or enter the bloodstream and act
on distant structures (endocrine mode of action). Reproduced from El-
Salhy et al. [13] with permission from the authors and publisher
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hormones regulate visceral sensation, motility, secretion, absorp-
tion, the local immune defense system, cell proliferation, and
appetite [2, 73, 87–89]. Patients with IBS exhibit gut dysmotility,
visceral hypersensitivity, and abnormal secretion [90]. The den-
sities of enteroendocrine cells are generally lower in IBS patients
than in healthy subjects [91], and these abnormalities appear to
play a major role in the pathophysiology of IBS [90, 92]. It is
particularly interesting that the density of enteroendocrine cells in
the intestine did not differ between Thai IBS patients and healthy
controls, nor did the densities of stem cells or progenitors for
enteroendocrine cells [93, 94].
It is hypothesized that diet as a prebiotic can favor the
growth of certain bacteria. The fermentation products of such
a diet produced by these bacteria act on intestinal stem cells to
cause a low differentiation into endocrine cells. The resulting
low density of enteroendocrine cells and the subsequent low
levels of certain hormones give rise to intestinal dysmotility,
visceral hypersensitivity, and abnormal secretion (Fig. 3) [13].
This hypothesis is supported by the finding that changing
from the common Norwegian diet of IBS patients to a low-
FODMAP diet restored the density of GI cells to the levels in
healthy subjects (Figs. 4 and 5) [unpublished data, 95–102]. In
addition, Thai IBS patients consuming different favorable di-
ets for IBS did not show abnormalities in the enteroendocrine
cells [93, 94]. Moreover, fecal microbiota transplantation
changes the densities of intestinal endocrine cells in patients
with IBS towards those seen in healthy subjects [103]. These
changes in gut endocrine cells caused by a low-FODMAP diet
Fig. 3 Schematic illustration of the possible role of interactions between
diet, gut microbiota, and gut endocrine cells in the pathophysiology of
irritable bowel syndrome (IBS). The diet that we consume acts as a
prebiotic that favors the growth of certain types of bacteria. These
bacteria can in turn ferment the diet, resulting in by-products that may
act on the stem cells in a way that reduces their number. This in turn
would result in a low density of gut endocrine cells, which gives rise to
the gut dysmotility, visceral hypersensitivity, and abnormal gut secretion
seen in IBS patients. Reproduced from El-Salhy et al. [13] with permis-
sion from the authors and publisher
Fig. 4 Colonic chromogranin A cells in a healthy subject (a), in a patient
with irritable bowel syndrome (IBS) (b), and in a patient with IBS after
3 months on a low-FODMAP diet (c). Chromogranin A is a common
marker for enteroendocrine cells
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and fecal microbiota transplantation were accompanied by
improvements in symptoms and the quality of life [99].
Conclusion
Diet plays an important role in the pathophysiology of IBS by
interacting with other factors that affect the pathophysiology,
namely the intestinal bacterial flora and enteroendocrine cells.
Differences between Asian andWestern diets may account for
the differences between patients with IBS in Asia andWestern
countries, including in the prevalence, sex, and clinical
presentation.
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